TEVA PHARMACEUTICAL INDUSTRIES LTD Contracts & Agreements

Second Amendment to Senior Unsecured Sustainability-Linked Revolving Credit Agreement, dated May 3, 2024, by and among Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals... (Filed With SEC on May 8, 2024)

Employment Agreement, dated as of September 25, 2018, between Teva UK Limited and Richard Daniell (Filed With SEC on February 12, 2024)

Letter Agreement, dated as of February 11, 2022, between Teva Pharmaceuticals Europe and Richard Daniell (Filed With SEC on February 12, 2024)

Deferred Prosecution Agreement, dated August 21, 2023 (Filed With SEC on August 24, 2023)

Teva Global Opioids Settlement Agreement, effective on August 7, 2023, between Teva Pharmaceutical Industries Ltd. and the states, subdivisions and special districts named therein (Filed With SEC on August 2, 2023)

Letter Agreement, dated as of February 8, 2023, between Teva Pharmaceutical Industries Ltd. and Eric Drap (Filed With SEC on May 10, 2023)

Fourth Supplemental Senior Indenture, dated as of March 9, 2023, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New... (Filed With SEC on March 9, 2023)

Fourth Supplemental Senior Indenture, dated as of March 9, 2023, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New... (Filed With SEC on March 9, 2023)

Underwriting Agreement, dated as of March 1, 2023, among the Issuers, the Company, Citigroup Global Markets Europe AG, Citigroup Global Markets Inc., Goldman Sachs Bank Europe SE,... (Filed With SEC on March 3, 2023)

Amendment to Senior Unsecured Sustainability-Linked Revolving Credit Agreement, dated as of February 6, 2023, by and among Teva Pharmaceutical Industries Limited, Teva... (Filed With SEC on February 10, 2023)

Employment Agreement, dated November 21, 2022, between Teva Pharmaceutical Industries Limited and Richard D. Francis (Filed With SEC on February 10, 2023)

Letter Agreement, dated November 21, 2022, between Teva Pharmaceutical Industries Limited and Kre Schultz (Filed With SEC on February 10, 2023)

Letter Agreement, dated as of December 27, 2022, between Teva Pharmaceutical Industries and Eric Drape (Filed With SEC on February 10, 2023)

Employment Agreement, dated as of June 5, 2018, between Teva Pharmaceuticals USA, Inc. and Sven Dethlefs (Filed With SEC on February 9, 2022)

Amendment to Employment Agreement between Teva Pharmaceuticals USA, Inc. and Sven Dethlefs, dated as of July 18, 2018 (Filed With SEC on February 9, 2022)

Appointment Letter, dated as of July 27, 2021, of Mark Sabag (Filed With SEC on February 9, 2022)

Appointment Letter, dated as of July 27, 2021, of Sven Dethlefs (Filed With SEC on February 9, 2022)

Third Supplemental Senior Indenture, dated as of November 9, 2021, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New... (Filed With SEC on November 10, 2021)

Third Supplemental Senior Indenture, dated as of November 9, 2021, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of... (Filed With SEC on November 10, 2021)

Underwriting Agreement, dated as of November 2, 2021, among the Issuers, the Company, BNP Paribas, BNP Paribas Securities Corp., BofA Securities Europe SA, BofA Securities, Inc.,... (Filed With SEC on November 4, 2021)

Employment Agreement, dated as of March 12, 2020, between Teva Pharmaceutical Industries Limited and Eric Drap (Filed With SEC on February 10, 2021)

Employment Agreement, dated as of May 30, 2013, between Teva Sante and Eric Drap (Filed With SEC on February 10, 2021)

Transfer Agreement of Employment Contract, dated as of March 20, 2020, between Teva Sante, Teva Pharmaceutical Industries Limited and Eric Drap (Filed With SEC on February 10, 2021)

Form Award Agreement under Tevas 2020 Long-Term Equity-Based Incentive Plan (Filed With SEC on November 5, 2020)

Teva Pharmaceutical Industries Limited Israeli Subplan of Tevas 2020 Long-Term Equity-Based Incentive Plan (Filed With SEC on November 5, 2020)

Amendment No. 1 dated as of June 9, 2020, to the Employment Agreement between Teva Pharmaceutical Industries Limited and Kre Schultz (Filed With SEC on June 9, 2020)

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 21, 2020)

Separation Agreement, dated as of November 4, 2019, between Teva Pharmaceuticals USA, Inc. and Carlo de Notaristefani (Filed With SEC on February 21, 2020)

Employment Agreement, dated as of December 22, 2013, between Teva Pharmaceuticals USA Inc. and Brendan OGrady (Filed With SEC on February 21, 2020)

Employment Agreement, dated as of April 1, 2019, between Teva Pharmaceutical Industries Limited and Gianfranco Nazzi (Filed With SEC on February 21, 2020)

Employment Agreement, dated as of November 6, 2019, between Teva Pharmaceutical Industries Limited and Eli Kalif (Filed With SEC on February 21, 2020)

Form Special Award Letter applicable to selected 2017 grants made to Gianfranco Nazzi and Brendan OGrady (Filed With SEC on February 21, 2020)

Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2016 grants and 2017 grants made to... (Filed With SEC on February 21, 2020)

Form Award Agreement (RSUs and PSUs) under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan (Filed With SEC on February 21, 2020)

Amendment to Employment Agreement between Teva Pharmaceutical Industries Limited and Eli Kalif, dated as of February 6, 2020 (Filed With SEC on February 21, 2020)

Second Supplemental Senior Indenture, dated as of November 25, 2019, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New... (Filed With SEC on November 25, 2019)

Registration Rights Agreement, dated as of November 25, 2019, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited and the initial... (Filed With SEC on November 25, 2019)

Second Supplemental Senior Indenture, dated as of November 25, 2019, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of... (Filed With SEC on November 25, 2019)

Registration Rights Agreement, dated as of November 25, 2019, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and the initial... (Filed With SEC on November 25, 2019)

Amendment to Employment Agreement between Teva Pharmaceuticals USA, Inc. and Hafrun Fridriksdottir, dated as of January 4, 2019 (Filed With SEC on February 19, 2019)

Second Amended and Restated Deposit Agreement, by and among Teva Pharmaceutical Industries Limited and Citibank, N.A., as Depositary, and the holders and beneficial owners of... (Filed With SEC on December 4, 2018)

Long-Term Assignment Letter for Michael McClellan dated August 9, 2018 (Filed With SEC on November 1, 2018)

Senior Indenture, dated as of March 14, 2018, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as... (Filed With SEC on March 14, 2018)

First Supplemental Senior Indenture, dated as of March 14, 2018, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New... (Filed With SEC on March 14, 2018)

Registration Rights Agreement, dated as of March 14, 2018, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and the initial... (Filed With SEC on March 14, 2018)

Senior Indenture, dated as of March 14, 2018, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as... (Filed With SEC on March 14, 2018)

First Supplemental Senior Indenture, dated as of March 14, 2018, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New... (Filed With SEC on March 14, 2018)

Registration Rights Agreement, dated as of March 14, 2018, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited and the initial purchasers... (Filed With SEC on March 14, 2018)

Amendment, dated as of September 24, 2015, to the Senior Unsecured Fixed Rate Japanese Yen Term Loan Credit Agreement, dated as of March 28, 2012, among Teva Pharmaceutical... (Filed With SEC on February 12, 2018)

Amendment, dated as of September 24, 2015, to the Senior Unsecured Japanese Yen Term Loan Credit Agreement, dated as of December 17, 2013, among Teva Pharmaceutical Industries... (Filed With SEC on February 12, 2018)

Amendment, dated as of July 21, 2016, to the Senior Unsecured Revolving Credit Agreement, dated as of November 16, 2015, by and among Teva Pharmaceutical Industries Limited, as... (Filed With SEC on February 12, 2018)

Employment Agreement, dated September 7, 2017, between Teva Pharmaceutical Industries Limited and Kre Schultz (Filed With SEC on February 12, 2018)

Employment Agreement, dated January 15, 2014, between Teva Pharmaceutical Industries Limited and Erez Vigodman (Filed With SEC on February 12, 2018)

Employment Agreement, dated as of February 6, 2017, between Teva Pharmaceutical Industries Limited and Yitzhak Peterburg (Filed With SEC on February 12, 2018)

Employment Agreement, dated as of August 7, 2008, between Teva Pharmaceutical Industries Limited and Eyal Desheh (Filed With SEC on February 12, 2018)

Addendum to Employment Agreement between Teva Pharmaceutical Industries Limited and Eyal Desheh, dated as of August 7, 2008 (Filed With SEC on February 12, 2018)

Amendment to Employment Agreement between Teva Pharmaceutical Industries Limited and Eyal Desheh, dated as of October 2012 (Filed With SEC on February 12, 2018)

Termination Agreement, dated as of January 22, 2018, between Teva Pharmaceutical Industries Limited and Eyal Desheh (Filed With SEC on February 12, 2018)

Employment Agreement, dated as of February 8, 2018, between Teva Pharmaceuticals USA, Inc. and Michael McClellan (Filed With SEC on February 12, 2018)

Letter Agreement, dated as of July 19, 2017, between Teva Pharmaceuticals USA, Inc. and Michael McClellan (Filed With SEC on February 12, 2018)

Letter Agreement, dated as of September 19, 2017, between Teva Pharmaceuticals USA, Inc. and Michael McClellan (Filed With SEC on February 12, 2018)

Letter Agreement, dated as of April 26, 2017, between Teva Pharmaceuticals USA, Inc. and Michael McClellan (Filed With SEC on February 12, 2018)

Amended and Restated Employment Agreement, dated as of February 7, 2018, between Teva Pharmaceuticals USA, Inc. and Carlo de Notaristefani (Filed With SEC on February 12, 2018)

Employment Agreement, dated as of June 18, 2017, between Teva Pharmaceuticals USA, Inc. and Hafrun Fridriksdottir (Filed With SEC on February 12, 2018)

Letter Agreement, dated as of February 21, 2016, between Teva Pharmaceuticals USA, Inc. and Hafrun Fridriksdottir (Filed With SEC on February 12, 2018)

Letter Agreement, dated as of December 1, 2016, between Teva Pharmaceuticals USA, Inc. and Hafrun Fridriksdottir (Filed With SEC on February 12, 2018)

Letter Agreement, dated as of November 7, 2016, between Teva Pharmaceuticals USA, Inc. and Hafrun Fridriksdottir (Filed With SEC on February 12, 2018)

Letter Agreement, dated as of July 28, 2015, between Teva Pharmaceutical Industries Limited and Hafrun Fridriksdottir (Filed With SEC on February 12, 2018)

Employment Agreement, dated as of December 22, 2013, between Teva Pharmaceutical Industries Limited and Mark Sabag (Filed With SEC on February 12, 2018)

Letter Agreement, dated as of June 2017, between Teva Pharmaceutical Industries Limited and Mark Sabag (Filed With SEC on February 12, 2018)

Employment Agreement, dated as of December 21, 2011, between Teva Pharmaceuticals Europe B.V. and Rob Koremans (Filed With SEC on February 12, 2018)

First Amendment to Employment Agreement between Teva Pharmaceuticals Europe B.V. and Rob Koremans, dated as of October 30, 2012 (Filed With SEC on February 12, 2018)

Second Amendment to Employment Agreement between Teva Pharmaceuticals Europe B.V. and Rob Koremans, dated as of January 12, 2015 (Filed With SEC on February 12, 2018)

Third Amendment to Employment Agreement between Teva Pharmaceuticals Europe B.V. and Rob Koremans, dated as of September 18, 2017 (Filed With SEC on February 12, 2018)

Termination Agreement, dated as of January 25, 2018, between Teva Pharmaceuticals Europe B.V. and Rob Koremans (Filed With SEC on February 12, 2018)

Amended and Restated Employment Agreement, dated as of May 22, 2015, between Teva Pharmaceutical Industries Limited and Dr. Michael Hayden (Filed With SEC on February 12, 2018)

Letter Agreement, dated as of May 8, 2012, between Teva Pharmaceutical Industries Limited and Dr. Michael Hayden (Filed With SEC on February 12, 2018)

2017 Form Bonus Letter Agreement, applicable to Rob Koremans, Dr. Michael Hayden, Hafrun Fridriksdottir, Carlo de Notaristefani, Eyal Desheh and Mark Sabag (Filed With SEC on February 12, 2018)

Teva Pharmaceuticals USA, Inc. Supplemental Deferred Compensation Plan (Filed With SEC on February 12, 2018)

Teva Pharmaceuticals USA, Inc. Defined Contribution Supplemental Executive Retirement Plan (Filed With SEC on February 12, 2018)

Form of Indemnification and Release Agreement (Filed With SEC on February 12, 2018)

Form Director Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2015, 2016 and 2017 grants (Filed With SEC on February 12, 2018)

Hafrun Fridriksdottir Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2016 grants (Filed With SEC on February 12, 2018)

Kre Schultz Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to November 3, 2017 grant (Filed With SEC on February 12, 2018)

Carlo de Notaristefani Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to May 18, 2017 grant (Filed With SEC on February 12, 2018)

Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2016 grants made to Michael McClellan and... (Filed With SEC on February 12, 2018)

Hafrun Fridriksdottir Substitute Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to August 2, 2016 stock... (Filed With SEC on February 12, 2018)

Hafrun Fridriksdottir Substitute Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to August 2, 2016... (Filed With SEC on February 12, 2018)

Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2015 grants made to Michael McClellan (Filed With SEC on February 12, 2018)

Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2017 grants made to Mark Sabag, Michael... (Filed With SEC on February 12, 2018)

Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2016 grants made to Mark Sabag, Carlo de... (Filed With SEC on February 12, 2018)

Form Award Agreement under the Teva Pharmaceutical Industries Limited 2010 Long-Term Equity-Based Incentive Plan applicable to selected 2015 grants made to Mark Sabag, Carlo de... (Filed With SEC on February 12, 2018)

Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2018 grants made to Kre Schultz, Michael... (Filed With SEC on February 12, 2018)

2018 Form Bonus Letter Agreement (Filed With SEC on February 12, 2018)

Michael McClellan Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to September 18, 2017 grant (Filed With SEC on February 12, 2018)

Settlement Agreement and Mutual Releases Agreement, dated as of January 31, 2018, by and between Teva Pharmaceutical Industries Ltd. and Allergan plc (Filed With SEC on February 12, 2018)

Amendment to the Senior Unsecured Revolving Credit Agreement dated as of November 16, 2015 (Filed With SEC on February 1, 2018)

Amendment to the Term Loan Credit Agreement dated as of November 16, 2015 (Filed With SEC on February 1, 2018)

Amendment to the Senior Unsecured Fixed Rate Japanese Yen Term Loan Credit Agreement, dated as of March 28, 2012 (Filed With SEC on February 1, 2018)

Amendment to the Senior Unsecured Japanese Yen Term Loan Credit Agreement, dated as of December 17, 2013 (Filed With SEC on February 1, 2018)

Amendment to the Senior Unsecured Japanese Yen Term Loan Credit Agreement, dated as of March 22, 2017 (Filed With SEC on February 1, 2018)

Category

Industry

Companies

Contracts

TEVA PHARMACEUTICAL INDUSTRIES LTD Contracts & Agreements